ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
ChemoCentryx (CCXI) Tops Q3 EPS by 13c
November 9, 2021 5:09 PM ESTChemoCentryx (NASDAQ: CCXI) reported Q3 EPS of ($0.32), $0.13 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $17.7 million versus the consensus estimate of $13.48 million.
For earnings history and earnings-related data on ChemoCentryx (CCXI) click here.
... More